Galapagos Nv (NASDAQ: GLPG)

Galapagos NV is a biotechnology company that discovers develops and advances therapeutic programs for patients with serious diseases. The company focuses on immunology and oncology areas seeking to deliver meaningful medicines through a modality agnostic approach. It leverages its dealmaking expertise and capital to identify acquire and progress promising assets from early research to clinical proof of concept. Galapagos NV maintains its headquarters in Mechelen Belgium and operates with a lean organization designed to support strategic business development. The firm aims to build a pipeline that addresses high unmet medical need while creating value for patients and shareholders.

Galapagos NV generates revenue primarily from upfront payments milestone payments and royalties earned under its collaboration agreements. The company received a substantial upfront payment and equity investment from Gilead under the ten year global R&D collaboration known as OLCA and continues to earn tiered royalties on net sales of licensed programs outside Europe. It also obtained an upfront payment and potential milestone earn outs from the transfer of its Jyseleca business to Alfasigma S.p. A. Additional revenue streams include milestone payments from distribution partners such as Sobi for Jyseleca in certain territories and fees for contracted research services with organizations like NovAliX. The firm’s total net revenues reached €1 112 2 million for the year ended December 31 2025 reflecting the release of deferred income related to the OLCA with Gilead as well as ongoing collaboration activity.

The company operates through a single operating segment that encompasses all of its discovery development and commercialization activities. This segment integrates its immunology and oncology programs including small molecule and cell therapy initiatives under one management structure. Reporting is consolidated at the company level without geographical division.

• The single operating segment is responsible for identifying acquiring and advancing therapeutic candidates in immunology and oncology. It conducts early stage research preclinical development and clinical trials for programs such as the TYK2 inhibitor GLPG3667 and the CAR T cell therapies GLPG5101 and GLPG5301. The segment also manages partnership negotiations collaboration agreements and the execution of business development transactions aimed at building a de risked pipeline. All operational functions including finance legal and scientific teams support this segment to drive value creation for patients and shareholders.

Galapagos NV competes in the highly competitive biotechnology sector where it faces large pharmaceutical companies and specialized biotech firms. In the immunology space its TYK2 inhibitor GLPG3667 rivals agents such as deucravacitinib from BMS upadacitinib from Abbvie and cenerimod from Idorsia. In systemic lupus erythematosus the company contends with approved therapies like belimumab from GSK and anifrolumab from AstraZeneca as well as numerous phase three candidates. Its competitive advantages stem from a modality agnostic investment approach a strong capital base and the strategic partnership with Gilead that provides financial resources regulatory expertise and commercial reach. The company’s dealmaking track record and ability to acquire and de risk early stage assets further differentiate it from peers that rely solely on internal discovery.

Galapagos NV serves patients with autoimmune diseases and cancer through its therapeutic programs while its direct customers are primarily pharmaceutical and biotechnology partners. The company collaborates with Gilead under the OLCA agreement and has transferred its Jyseleca business to Alfasigma S.p. A. It works with distribution partners such as Sobi for certain territories and engages contract research organizations like NovAliX for discovery services. Additionally Galapagos NV interacts with clinical trial sites hospitals and healthcare providers that administer its investigational medicines to enrolled patients. These relationships enable the company to advance its pipeline generate revenue and ultimately deliver medicines to those in need.